A Guide to New and Emerging Treatment Options for Chronic CoughPremiere Date: Tuesday, August 3, 2021
This activity offers CE credit for:%>
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, August 3, 2022
Note: Credit Is No Longer Available
|Mandel R. Sher, MD (Moderator)
Founder, Sher Allergy Specialists
Founder, Center for Cough
Clinical Professor of Medicine and Pediatrics
Division of Allergy & Immunology
University of South Florida, Morsani College of Medicine, Johns Hopkins All Children's Hospital
St. Petersburg, FL
|Nur Kazzaz, PharmD, BCPS
Clinical Pharmacy Specialist in Pulmonary Medicine
Temple University Hospital, Lung Center
While the last approved cough agent was in 1958, there are emerging chronic cough treatments in trials, particularly in a new class of agents called P2X3 receptor antagonists. Pharmacists should evaluate efficacy and safety data for new and emerging treatments in order to counsel patients and help patients on their journey to diagnosis and finding an acceptable cough therapy.
In this CME Outfitters podcast, expert faculty will discuss new concepts related to our understanding of cough hypersensitivity and the data emerging from trials of new agents to build the foundation of these novel, targeted mechanisms, and the promise of these drug therapies to address unmet needs in chronic cough.
At the end of this CE activity, participants should be able to:
- Evaluate efficacy and safety data for new and emerging treatments for chronic cough.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hours (0.05 CEUs) Universal Activity Number: Live: JA0007185-0000-21-140-H01-P
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Sher reports that he receives research support from Bayer; Bellus Health Inc.; Merck & Co., Inc; and Shionogi Inc. He is a consultant for Bayer; Bellus Health Inc.; Merck & Co., Inc.; Shionogi Inc.; Nocion Therapeutics Inc; and NeRRe Therapeutics.
Dr. Kazzaz has no disclosures to report.
Julie Strickland, PharmD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).